Yearly Archives: 2013

Drug Patent Expirations for March 2013

Tradename Applicant Generic Name Patent Number Patent Expiration
THALOMID Celgene thalidomide 8,143,283 Mar 1, 2013
THALOMID Celgene thalidomide 7,723,361 Mar 1, 2013
THALOMID Celgene thalidomide 6,235,756 Mar 1, 2013
ZOMETA Novartis zoledronic acid 4,939,130*PED Mar 2, 2013
LUNESTA Sunovion Pharms Inc eszopiclone 6,864,257*PED Mar 2, 2013
RECLAST Novartis zoledronic acid 4,939,130*PED Mar 2, 2013
NATROBA Parapro Llc spinosad 5,496,931 Mar 5, 2013
FLO-PRED Taro prednisolone acetate 6,102,254 Mar 11, 2013
ABRAXANE Abraxis Bioscience paclitaxel 5,498,421 Mar 12, 2013
COMBIVENT RESPIMAT Boehringer Ingelheim albuterol sulfate; ipratropium bromide 5,497,944 Mar 12, 2013
RYBIX ODT Shionogi Inc tramadol hydrochloride 5,464,632 Mar 22, 2013
XOPENEX Sunovion levalbuterol hydrochloride 5,362,755 Mar 25, 2013
XOPENEX HFA Sunovion levalbuterol tartrate 5,362,755 Mar 25, 2013
SILENOR Somaxon doxepin hydrochloride 5,502,047 Mar 26, 2013
LOVAZA Smithkline Beecham omega-3-acid ethyl esters 5,502,077 Mar 26, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for February 20 2013

TradenameApplicantGeneric Name Patent Expiration
ARRANONSmithkline BeechamnelarabineFeb 20, 2013

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Infographics

Top
selling drugs

What are the Top-selling Drugs?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.